flutamide has been researched along with Weight Gain in 4 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We previously reported better control of linear growth, weight gain, and bone maturation in a short term cross-over study of a new four-drug treatment regimen containing an antiandrogen (flutamide), an inhibitor of androgen to estrogen conversion (testolactone), reduced hydrocortisone dose, and fludrocortisone, compared to the effects of a control regimen of hydrocortisone and fludrocortisone." | 9.09 | Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. ( Cutler, GB; Fields, J; Hill, S; Jones, JV; Keil, MF; Merke, DP, 2000) |
| "Treatment outcome in congenital adrenal hyperplasia is often suboptimal due to hyperandrogenism, treatment-induced hypercortisolism, or both." | 6.68 | A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia. ( Barnes, KM; Cutler, GB; Hill, S; Jones, JV; Laue, L; Merke, DP, 1996) |
| " We previously reported better control of linear growth, weight gain, and bone maturation in a short term cross-over study of a new four-drug treatment regimen containing an antiandrogen (flutamide), an inhibitor of androgen to estrogen conversion (testolactone), reduced hydrocortisone dose, and fludrocortisone, compared to the effects of a control regimen of hydrocortisone and fludrocortisone." | 5.09 | Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. ( Cutler, GB; Fields, J; Hill, S; Jones, JV; Keil, MF; Merke, DP, 2000) |
| "Treatment outcome in congenital adrenal hyperplasia is often suboptimal due to hyperandrogenism, treatment-induced hypercortisolism, or both." | 2.68 | A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia. ( Barnes, KM; Cutler, GB; Hill, S; Jones, JV; Laue, L; Merke, DP, 1996) |
| "Flutamide treatment for 4 weeks resulted in decreased organ weights of the epididymides and prostate, decreased sperm counts and Leydig cell proliferation in the testes at 60 mg/kg and 200 mg/kg." | 1.31 | Collaborative work to evaluate toxicity on male reproductive organs by repeated dose studies in rats 5). Effects of repeated doses of flutamide for 2 and 4 weeks. ( Ikuse, T; Nomura, A; Okahara, A; Sakamoto, H; Tanioka, H; Yamashita, K, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Laue, L | 1 |
| Merke, DP | 2 |
| Jones, JV | 2 |
| Barnes, KM | 1 |
| Hill, S | 2 |
| Cutler, GB | 2 |
| Keil, MF | 1 |
| Fields, J | 1 |
| Pazos, F | 1 |
| Sánchez-Franco, F | 1 |
| Balsa, JA | 1 |
| Escalada, J | 1 |
| Palacios, N | 1 |
| Cacicedo, L | 1 |
| Okahara, A | 1 |
| Nomura, A | 1 |
| Tanioka, H | 1 |
| Sakamoto, H | 1 |
| Yamashita, K | 1 |
| Ikuse, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Novel Therapeutic Modality for Congenital Adrenal Hyperplasia[NCT00529841] | 7 participants (Actual) | Interventional | 2007-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for flutamide and Weight Gain
| Article | Year |
|---|---|
A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Hyperplasia, Congenital; Adrenocorticotropic Hormone; Bone Dev | 1996 |
Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia.
Topics: Adrenal Hyperplasia, Congenital; Androgen Antagonists; Androgens; Anti-Inflammatory Agents; Antineop | 2000 |
2 other studies available for flutamide and Weight Gain
| Article | Year |
|---|---|
Mechanisms of reduced body growth in the pubertal feminized male rat: unbalanced estrogen and androgen action on the somatotropic axis.
Topics: Aging; Androgen Receptor Antagonists; Animals; Flutamide; Gene Expression Regulation; Growth Hormone | 2000 |
Collaborative work to evaluate toxicity on male reproductive organs by repeated dose studies in rats 5). Effects of repeated doses of flutamide for 2 and 4 weeks.
Topics: Administration, Oral; Androgen Antagonists; Animals; Dose-Response Relationship, Drug; Flutamide; Ma | 2000 |